Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study

Anna Moltó, Adrien Etcheto, Désirée van der Heijde, Robert Landewé, Filip van den Bosch, Wilson Bautista Molano, Ruben Burgos-Vargas, Peter P. Cheung, Eduardo Collantes-Estevez, Atulya (Atul) Deodhar, Bassel El-Zorkany, Shandor Erdes, Jieruo Gu, Najia Hajjaj-Hassouni, Uta Kiltz, Tae Hwan Kim, Mitsumasa Kishimoto, Shue Fen Luo, Pedro M. Machado, Walter P. MaksymowychJosé Maldonado-Cocco, Helena Marzo-Ortega, Carlo Maurizio Montecucco, Salih Ozgoçmen, Floris van Gaalen, Maxime Dougados

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. Results The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities. Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
DOIs
StateAccepted/In press - Mar 15 2016

Fingerprint

Comorbidity
Screening
Blood pressure
Osteoporosis
Cardiovascular Infections
LDL Cholesterol
Blood Pressure
Statistical methods
Gastrointestinal Neoplasms
Cholesterol
Practice Management
Hypercholesterolemia
Peptic Ulcer
Taiwan
Monitoring
Germany
Cross-Sectional Studies
Smoking
Hypertension

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis : Results of the international cross-sectional ASAS-COMOSPA study. / Moltó, Anna; Etcheto, Adrien; van der Heijde, Désirée; Landewé, Robert; van den Bosch, Filip; Molano, Wilson Bautista; Burgos-Vargas, Ruben; Cheung, Peter P.; Collantes-Estevez, Eduardo; Deodhar, Atulya (Atul); El-Zorkany, Bassel; Erdes, Shandor; Gu, Jieruo; Hajjaj-Hassouni, Najia; Kiltz, Uta; Kim, Tae Hwan; Kishimoto, Mitsumasa; Luo, Shue Fen; Machado, Pedro M.; Maksymowych, Walter P.; Maldonado-Cocco, José; Marzo-Ortega, Helena; Montecucco, Carlo Maurizio; Ozgoçmen, Salih; van Gaalen, Floris; Dougados, Maxime.

In: Annals of the Rheumatic Diseases, 15.03.2016.

Research output: Contribution to journalArticle

Moltó, A, Etcheto, A, van der Heijde, D, Landewé, R, van den Bosch, F, Molano, WB, Burgos-Vargas, R, Cheung, PP, Collantes-Estevez, E, Deodhar, AA, El-Zorkany, B, Erdes, S, Gu, J, Hajjaj-Hassouni, N, Kiltz, U, Kim, TH, Kishimoto, M, Luo, SF, Machado, PM, Maksymowych, WP, Maldonado-Cocco, J, Marzo-Ortega, H, Montecucco, CM, Ozgoçmen, S, van Gaalen, F & Dougados, M 2016, 'Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208174
Moltó, Anna ; Etcheto, Adrien ; van der Heijde, Désirée ; Landewé, Robert ; van den Bosch, Filip ; Molano, Wilson Bautista ; Burgos-Vargas, Ruben ; Cheung, Peter P. ; Collantes-Estevez, Eduardo ; Deodhar, Atulya (Atul) ; El-Zorkany, Bassel ; Erdes, Shandor ; Gu, Jieruo ; Hajjaj-Hassouni, Najia ; Kiltz, Uta ; Kim, Tae Hwan ; Kishimoto, Mitsumasa ; Luo, Shue Fen ; Machado, Pedro M. ; Maksymowych, Walter P. ; Maldonado-Cocco, José ; Marzo-Ortega, Helena ; Montecucco, Carlo Maurizio ; Ozgoçmen, Salih ; van Gaalen, Floris ; Dougados, Maxime. / Prevalence of comorbidities and evaluation of their screening in spondyloarthritis : Results of the international cross-sectional ASAS-COMOSPA study. In: Annals of the Rheumatic Diseases. 2016.
@article{1e83605a17e14aa4a5968a1645b760d8,
title = "Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study",
abstract = "Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. Results The most frequent comorbidities were osteoporosis (13{\%}) and gastroduodenal ulcer (11{\%}). The most frequent risk factors were hypertension (34{\%}), smoking (29{\%}) and hypercholesterolaemia (27{\%}). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8{\%} (Taiwan) to 98{\%} (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14{\%})), emphasising the suboptimal monitoring of comorbidities. Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.",
author = "Anna Molt{\'o} and Adrien Etcheto and {van der Heijde}, D{\'e}sir{\'e}e and Robert Landew{\'e} and {van den Bosch}, Filip and Molano, {Wilson Bautista} and Ruben Burgos-Vargas and Cheung, {Peter P.} and Eduardo Collantes-Estevez and Deodhar, {Atulya (Atul)} and Bassel El-Zorkany and Shandor Erdes and Jieruo Gu and Najia Hajjaj-Hassouni and Uta Kiltz and Kim, {Tae Hwan} and Mitsumasa Kishimoto and Luo, {Shue Fen} and Machado, {Pedro M.} and Maksymowych, {Walter P.} and Jos{\'e} Maldonado-Cocco and Helena Marzo-Ortega and Montecucco, {Carlo Maurizio} and Salih Ozgo{\cc}men and {van Gaalen}, Floris and Maxime Dougados",
year = "2016",
month = "3",
day = "15",
doi = "10.1136/annrheumdis-2015-208174",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Prevalence of comorbidities and evaluation of their screening in spondyloarthritis

T2 - Results of the international cross-sectional ASAS-COMOSPA study

AU - Moltó, Anna

AU - Etcheto, Adrien

AU - van der Heijde, Désirée

AU - Landewé, Robert

AU - van den Bosch, Filip

AU - Molano, Wilson Bautista

AU - Burgos-Vargas, Ruben

AU - Cheung, Peter P.

AU - Collantes-Estevez, Eduardo

AU - Deodhar, Atulya (Atul)

AU - El-Zorkany, Bassel

AU - Erdes, Shandor

AU - Gu, Jieruo

AU - Hajjaj-Hassouni, Najia

AU - Kiltz, Uta

AU - Kim, Tae Hwan

AU - Kishimoto, Mitsumasa

AU - Luo, Shue Fen

AU - Machado, Pedro M.

AU - Maksymowych, Walter P.

AU - Maldonado-Cocco, José

AU - Marzo-Ortega, Helena

AU - Montecucco, Carlo Maurizio

AU - Ozgoçmen, Salih

AU - van Gaalen, Floris

AU - Dougados, Maxime

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. Results The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities. Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.

AB - Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. Results The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities. Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.

UR - http://www.scopus.com/inward/record.url?scp=84962274738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962274738&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2015-208174

DO - 10.1136/annrheumdis-2015-208174

M3 - Article

C2 - 26489703

AN - SCOPUS:84962274738

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -